Kristin Price, MS, CGC
@k_sedgeProduct leader @guardanthealth. Specializing in ctDNA & developing tools to support more personalized oncology care. Minnesotan to Bostonian but commutes to SF.
Similar User
@carrie_haverty
@lazgabe
@LeighaSenter
@Mireille_Clou
@AlexisCarere
@NicolaCadenas
👀👇our early experience w/periop #ctDNA for pts w/ #livermetastases from #colorectalcancer. Some “cleared” by surgery! Do you use this biomarker in care of pts w/CLM? @VautheyMD @skopetz @colontown @manjuggm @MDAndersonNews @AnnalsofSurgery #oncsurgery pubmed.ncbi.nlm.nih.gov/35797554/
Less patients getting unnecessary chemotherapy is a HUGE win. So exciting to see this clinical utility data from ctDNA MRD testing.
DYNAMIC: Among patients with stage II colon cancer, a ctDNA-guided management approach reduced the use of adjuvant chemotherapy without increasing the risk of recurrence. #ASCO22 nej.md/3x0jR94
Congratulations to Dr. Kobayashi, Dr. Jänne and team @DanaFarber on the discovery of a silent mutation required to produce a functional KRAS Q61K & the @Nature pub. Thanks for letting me and @GuardantHealth be a part of this very cool work! nature.com/articles/s4158…
Very proud of our new paper: Common germline-somatic variant interactions in advanced urothelial cancer nature.com/articles/s4146… Tweetorial to follow.
A great story of hope. We have so far to go to improve cancer treatment, but there have been amazing improvements giving patients more time with they people they love (and more quality time on less toxic drugs). This is what motivates me. nytimes.com/2021/09/27/hea…
We’re excited to launch Guardant Reveal, the first blood-only #liquidbiopsy test for residual disease and recurrence monitoring of early-stage #colorectalcancer patients. #MRD bit.ly/3an9LUi
Pralsetinib (BLU-667), #RET inhibitor is now FDA approved, further expanding treatment options for our patients. Congratulations to @JustinGainor and co-investigators, and thanks to all patients and families for their contributions! onclive.com/view/fda-appro… #NSCLC #LCSM
non-smoker in 40s with egfr/alk/ros -/ pd-l1 high+ lung adeno from OSH after chemo/io failure w leptomeningeal disease, pall care discussed ?Can we just send 2 tubes of blood? Results:👇 We should rename NGS➡️ NMP (no malpractice) - might make it easier to remember to order it...
Important to remember to #Test for #Actionable Mutations using #NGS in patients with metastatic #NSCLC prior to using immunotherapy. #Plasma is a meaningful way to test. There are important efficacy and toxicity implications. Nicely summarized by @Tony_Calles et al #ASCO20
📚 Glad to share our book chapter in the 2020 @ASCO Educational Book: 'Checkpoint Blockade in Lung Cancer With Driver Mutation: Choose the Road Wisely'. 👉 Free access! #LCSM #OncoAlert #ASCO20 #EdBook #ImmunOnc ascopubs.org/doi/abs/10.120…
This is fantastic news! We now have access to a highly active RET inhibitor. prnewswire.com/news-releases/…
Great to see the PROfound trial in #NEJM showing benefit for olaparib in #mCRPC pts w/ #BRCA1/2 and #ATM muts. It will be important to ensure all patients get tested- somatic & germline. Interested to see response breakdown by mutation type. #GCchat nejm.org/doi/full/10.10…
Definitely time to add #MetExon14 to testing at diagnosis for all lung cancer patients? I say yes!
Garon: capmatinib in GEOMETRY study #MetExon14 pts. Impressive ORR 41% in 69 pre-treated pts and 68% in 28 rx-naive pts. Early data on CNS responses promising. AE's very tolerable, mostly LE swelling, nausea. This is exciting data! #AACR2020 #LCSM #OncoAlert
Encorafenib/Cetuximab Combo now FDA approved for #BRAF pos #mCRC. Data we published last year with @cotahealthcare showed that testing rates for BRAF in 2017 were around 50%. Let's make sure more patients get access to comprehensive testing in 2020. onclive.com/web-exclusives…
Here’s a useful overview of the likely scenarios that the world will be facing in the coming months while managing this pandemic. So much depends on our ability to make good decisions going forward along with our ability to remain resilient. theatlantic.com/health/archive…
ICYMI: #Osimertinib plus #savolitinib in patients with #EGFR mutation-positive, MET-amplified, #nonsmallcelllungcancer after progression on EGFR tyrosine kinase inhibitors: interim results from the phase 1b TATTON study thelancet.com/journals/lanon…
So sad that #patients who are not tested risk getting less than the best treatment for their #colorectalcancer. #GI20 @FightCRC
Molecular testing including MSI status, KRAS, NRAS, BRAF should be tested for all mCRC cases. Currently tested in about 50% of cases. @ASCO @COLONTOWN #gi20 #colorectalcancer #CRCSM
United States Trends
- 1. Cubs 26,2 B posts
- 2. #CUTOSHI 6.516 posts
- 3. CORY 37,3 B posts
- 4. Astros 18,7 B posts
- 5. Friday the 13th 125 B posts
- 6. Bregman 6.727 posts
- 7. Devin Williams 16,1 B posts
- 8. Cam Smith 6.011 posts
- 9. #SantaChat 8.149 posts
- 10. taemin 25 B posts
- 11. Bellinger 6.977 posts
- 12. Luxembourg 24,2 B posts
- 13. $DUCK 10,4 B posts
- 14. Nestor 16,3 B posts
- 15. Paredes 13,8 B posts
- 16. #JoyfullyRoku N/A
- 17. mark lee 24,9 B posts
- 18. Brewers 12,4 B posts
- 19. Big Bass Christmas Bash N/A
- 20. Durbin 7.110 posts
Something went wrong.
Something went wrong.